Pfizer's RSVpreF vaccine is in hot pursuit of GSK's shot, with results due to be reported very soon from the phase 3 RENOIR trial in older adults. It is also being developed for use in pregnant ...

The RSVPreF vaccine is safe and demonstrates immunobridging to efficacy among adults aged 18 to 59 who are at high risk for severe RSV disease.

Pfizer and BioNTech have started a mid-stage trial of a new version of the COVID-19 vaccine based on a version of the spike protein that they hope will offer greater and broader protection against ...

Respiratory syncytial virus prefusion F (RSVpreF) vaccine significantly reduced ... This study was funded by Pfizer. Several authors declared receiving grants and personal fees from Pfizer paid ...

Several authors disclosed ties to biopharmaceutical companies, including Pfizer, which manufactures the RSVpreF vaccine and funded the study. Abstract/Full Text ...